Free Newsletter
Duke researchers to test mosaic HIV vax candidate
Duke University researchers are assembling an international team to design the first human trial of a mosaic HIV vaccine candidate. Unlike traditional HIV vaccines that are designed to stimulate the immune system to recognize naturally occurring stretches of specific amino acids, mosaic vaccines are composed of many sets of synthetic, computer-generated sequences of proteins that can prompt the immune system to respond to a variety of strains. Such vaccines have shown success in animal studies, and trial will test the mosaic concept and could possibly lead to the next generation of HIV vaccine candidates.
Barton Haynes, who will lead the consortium, says the group will use the NYVAC vaccinia vector and DNA that contain a new set of artificial computer-designed HIV genes in a Phase I clinical trial that will be supported by the Bill & Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases.
Haynes says the consortium hopes to launch human trials by late 2012.
- get the Duke University release
Related Articles:
HIV vaccine researchers ponder new strategies, drop in funding
AIDS vax group reveals global research strategy
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: